Seaport’s IPO adventure, obesity pill battles, and Makary’s troubles

The Readout LOUD Seaport’s IPO adventure, obesity pill battles, and Makary’s troubles Manage alerts for this article Email this article Share this article By Allison DeAngelis, Elaine Chen, and Adam FeuersteinMay 7, 2026 Allison DeAngelis[email protected]Allison DeAngelis is the East Coast biotech and venture capital reporter at STAT, reporting where scientific ideas and money meet. She is also co-host of the weekly biotech podcast, The Readout Loud. You can reach Allison on Signal at AllisonDeAngelis.01.Elaine Chen[email protected]Elaine Chen covers biotech, co-writes The Readout newsletter, and co-hosts STAT’s weekly biotech podcast, The Readout Loud. You can reach Elaine on Signal at elaineywchen.70.Adam Feuerstein[email protected]Adam Feuerstein is a senior writer and biotech columnist, reporting on the crossroads of drug development, business, Wall Street, and biotechnology. He is also a co-host of the weekly biotech podcast The Readout Loud and author of the newsletter Adam’s Biotech Scorecard. You can reach Adam on Signal at stataf.54. On this week’s episode of “The Readout LOUD,” we chat with Seaport Therapeutics CEO Daphne Zohar, fresh off the biotech’s successful IPO. Plus, Elaine, Allison, and Adam chat about this week’s notable news, including the obesity pill battle between Eli Lilly and Novo Nordisk, a Phase 3 study win for Cytokinetics, and FDA Commissioner Marty Makary’s White House troubles. Oh, by the way, this is the 400th episode of your favorite biotech podcast. Advertisement Be sure to sign up for “The Readout LOUD” on Apple Podcasts, Spotify, or wherever you get your podcasts. biotechnology, FDA, Obesity, Pharmaceuticals, weight loss Submit a correction requestReprints Allison DeAngelis Biotech Startups and Venture Capital Reporter Allison DeAngelis is the East Coast biotech and venture capital reporter at STAT, reporting where scientific ideas and money meet. She is also co-host of the weekly biotech podcast, The Readout Loud. You can reach Allison on Signal at AllisonDeAngelis.01. Elaine Chen National Biotech Reporter Elaine Chen covers biotech, co-writes The Readout newsletter, and co-hosts STAT’s weekly biotech podcast, The Readout Loud. You can reach Elaine on Signal at elaineywchen.70. Adam Feuerstein Senior Writer, Biotech Adam Feuerstein is a senior writer and biotech columnist, reporting on the crossroads of drug development, business, Wall Street, and biotechnology. He is also a co-host of the weekly biotech podcast The Readout Loud and author of the newsletter Adam’s Biotech Scorecard. You can reach Adam on Signal at stataf.54. Newsletter Your morning rundown of the science, politics, and money driving biotech today Recommended The Readout LOUD April 30, 2026 STAT Plus: Hair-raising trial results, and Servier’s M&A wishlist The Readout LOUD April 24, 2026 STAT Plus: A biotech VC on what Eli Lilly saw in a struggling cancer startup for $3.2B Advertisement The Readout LOUD April 23, 2026 A CAR-T biotech’s dramatic turnaround, and drugmakers’ tactics to drive more scripts Biotech April 17, 2026 STAT Plus: A pancreatic cancer expert on why Revolution Medicines’ study could ‘open up a new era’ of treatment The Readout LOUD April 16, 2026 A pancreatic cancer breakthrough, and new hope for an off-the-shelf CAR-T treatment Subscriber Picks